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Goals: We assessed the efficacy of polaprezinc plus proton pump
inhibitor (PPI) treatment for endoscopic submucosal dissection (ESD)-
induced ulcer healing compared with rebamipide plus PPI treatment.
Background: ESD has been widely used as a local treatment option
that cures gastric neoplasms. However, it causes large and deep
artificial ulcers, and there are no guidelines with regard to the
optimal treatment durations and drug regimens for ESD-induced
ulcers. Polaprezinc is effective for promoting ulcer healing and helps
enhance the quality of ulcer healing.
Study: Two hundred ten patients with ESD-induced ulcers were
randomly allocated to treatment with polaprezinc (150 mg/d) plus
pantoprazole (40mg/d) or treatment with rebamipide (300mg/d)
plus pantoprazole (40mg/d). We evaluated the ulcer healing rate
and condition of the ulcer at 4 weeks after dissection. The χ2 or
Fisher exact test and the Student t test were used.
Results: The ulcer healing rates at 4 weeks after dissection in the
polaprezinc plus pantoprazole treatment group were not inferior
compared with those in the rebamipide plus pantoprazole treatment
group, both in the intention-to-treat analysis (90.3% and 91.4%,
respectively, P= 0.523) and per-protocol analysis (89.9% and
91.1%, respectively, P= 0.531). The short procedure time was an
independent predictive factor for a high ulcer healing rate (odds
ratio: 0.975; 95% confidence interval: 0.958-0.993; P= 0.006).
Conclusion: The polaprezinc plus PPI treatment showed non-
inferiority to rebamipide plus PPI treatment in the ulcer healing rate
at 4 weeks after ESD.
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E ndoscopic submucosal dissection (ESD) is widely used totreat gastric neoplasms.1 Although ESD shows higher en-
bloc and curative resection rates than endoscopic mucosal
resection, it causes larger and deeper artificial ulcers than
endoscopic mucosal resection. A larger artificial ulcer is a risk
factor of delayed bleeding.2
Therefore, the management of artificial ulcers is important.
Proton pump inhibitors (PPIs), histamine-2 receptor antagonists,
antacids, and mucosal protective drugs may heal artificial ulcers
induced by ESD faster. However, there is no consensus with
regard to optimal drugs and the proper duration. PPIs have been
known to be the most effective type of drug for the treatment of
artificial ulcers. However, in some studies, PPI monotherapy was
not sufficient to heal ESD-induced artificial ulcers.3
Rebamipide is a mucoprotective agent that accelerates
ulcer healing.4 Rebamipide increases the glycoprotein content
in gastric mucus and decreases reactive oxygen species.5,6
Therefore, it protects the gastric mucosa and promotes quality
of ulcer healing. Polaprezinc, a zinc-L-carnosine chelate com-
pound, is used for the treatment of gastric ulcer. It exerts gastric
mucosal protection and promotes ulcer healing through anti-
oxidant activity.7 There is a report that polaprezinc plus PPI
treatment prevented protrusion of the ulcer base during the
healing of ESD-induced artificial ulcers compared with PPI
monotherapy.8 In this study, we aimed to compare the rate of
ulcer healing between polaprezinc and PPI combination ther-
apy and rebamipide and PPI combination therapy.
METHODS
Patients
Between November 2014 and April 2016, we enrolled
patients who underwent ESD for gastric neoplasms for this
prospective, randomized, controlled study, which was con-
ducted at the 2 hospitals of Yonsei University College of
Medicine. Written informed consent was obtained from all
patients before study enrollment. Inclusion criteria were (1)
age 20 to 80 years and (2) patients pathologically diagnosed
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with gastric adenoma or cancer who were eligible for ESD.
Exclusion criteria were (1) use of medication such as PPIs,
histamine-2 receptor antagonists, or other mucosal protective
drugs within 2 weeks before enrollment; (2) those who
expected to take nonsteroidal anti-inflammatory drugs
(including aspirin) and steroids within 2 weeks before enroll-
ment; (3) history of upper gastrointestinal surgery; (4) history
of allergy to a PPI, rebamipide, or polaprezinc; and (5) sig-
nificant cardiovascular, renal, hepatic, neurotic, or psycho-
logical disorders.
The institutional review board of Severance and Gang-
nam Severance Hospitals approved this study. This study was
registered with clinicaltrials.gov (identifier 02243618).
Study Design (Sample Size, Randomization, and
Follow-up)
On the basis of a previous study,9 the ulcer healing rate
of the PPI and rebamipide arm after 4 weeks of admin-
istration was 95%, and the SD was 11%. The sample size
was calculated by using an α error of 0.025, statistical power
of 0.9, and 1-sided test. The calculated sample size was 103
lesions in each arm, for a total of 218 patients, allowing for a
5% dropout rate determined by assuming a noninferiority
margin of 5% and standard deviation of 11%.
A single study coordinator performed the randomization
process using a computer-generated randomization table.
Patients were randomly assigned to one of 2 groups (PPI plus
rebamipide or PPI plus polaprezinc). All patients received an
intravenous injection of 40mg of pantoprazole twice on the first
2 days after ESD. Beginning on the third day after ESD, the
patients in the PPI plus rebamipide group took 40mg of oral
pantoprazole once a day and 100mg rebamipide 3 times a day
for 28 days; the patients in the PPI plus polaprezinc group took
40mg of oral pantoprazole once a day and 75mg of polaprezinc
twice a day for 28 days.
The enrolled patients underwent follow-up endoscopy at 4
weeks after ESD to evaluate the degree of ulcer healing. The
adverse events and compliance with taking the drugs were
evaluated at 4 weeks. The patients who had low medication
compliance (<80%) and took the prohibited drugs mentioned in
the exclusion criteria were excluded in the per-protocol analysis.
Evaluation of the Primary and Secondary
Outcomes
The primary endpoint was the ulcer healing rate at 4 weeks,
which was calculated as follows: [(initial ulcer area−ulcer area at
4wk)×100/initial ulcer area]. The diameter of the ulcer was
measured by using an endoscopic forcep (Olympus Optical Co.
Ltd, Tokyo, Japan) (Supplementary Fig. 1, Supplemental Digi-
tal Content 1, http://links.lww.com/JCG/A558). Ulcer areas were
calculated by multiplying these 2 diameters. The secondary
endpoints were the proportion of patients based on the ulcer
stage, which was scarring, and quality of ulcer healing at 4
weeks. The ulcer stage was assessed by using the classification of
Sakita and Fukutomi,10 and described as active (A1, A2),
healing (H1, H2), and scarring (S1, S2) stages.
Statistical Analysis
The χ2 test or Fisher exact test was used to compare
categorical parameters. The Student t test was used to
compare continuous variables. Risk factors affecting the
ulcer healing rate were evaluated using logistic regression
analysis. The accepted significance level was P-value < 0.05.
All statistical analyses were performed using SPSS version
23.0 for Windows (SPSS Inc., Chicago, IL).
RESULTS
Baseline Characteristics
Among 218 patients, 109 patients each were randomly
allocated to the PPI plus rebamipide and PPI plus polaprezinc
FIGURE 1. Flow chart of patients. PP indicates per-protocol.
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group. Among them, 8 patients dropped out of the study
because of delayed bleeding (1 patient in the PPI plus reba-
mipide group), additive surgery owing to a positive resection
margin, or withdraw of informed consent. Thus, the 210
patients (106 in the PPI plus rebamipide group and 104 in the
PPI plus polaprezinc group) who completed the study protocol
were included in the full analysis. After excluding patients on
the basis of study protocols such as <80% drug compliance or
taking forbidden drugs, the data for 100 patients in the PPI plus
rebamipide group and 99 patients in the PPI plus polaprezinc
group were used in the per-protocol analysis (Fig. 1). There
were no significant differences between the 2 groups in terms of
age and sex, and histopathology, location, gross appearance,
and diameter of the tumor and in terms of ulcer size, en-bloc
resection rate, and procedure time.Helicobacter pylori infection
developed significantly more in the PPI plus rebamipide group
than in the PPI plus polaprezinc group (Table 1).
Healing Rates of Iatrogenic Ulcers at 4 Weeks
After ESD
The average ulcer healing rate of all patients at 4 weeks
after ESDwas 90.5%. The ulcer healing rate was not significantly
higher in the PPI plus rebamipide group than in the PPI plus
polaprezinc group, both in the full analysis (91.4%
and 90.3%, respectively; P=0.523) and per-protocol analysis
(91.1% and 89.9%, respectively; P=0.531). The percentage of
ulcers in the scarring stage at 4 weeks after ESD was not sig-
nificantly higher in the PPI plus rebamipide group than in the PPI
plus polaprezinc group, both in the full analysis (10.4% and 9.6%,
respectively; P=0.953) and per-protocol analysis (9.0% and
7.1%, respectively; P=0.846) (Table 2).
Subgroup Analysis of the Iatrogenic Ulcer
Healing Rates
We performed subgroup analysis to evaluate the risk factors
that affect the ulcer healing rate. There were no significant pre-
dictive factors for a superior ulcer healing rate between the PPI
plus rebamipide group and PPI plus polaprezinc group (Table 3).
In addition, we assessed the independent factors for predicting an
ulcer healing rate >90.5%, the mean average healing rate in this
study, in multivariate analysis. The procedure time was an
independent factor for a higher ulcer healing rate (Table 4).
DISCUSSION
In this study, the ulcer healing rates at 4 weeks after ESD
in the polaprezinc plus PPI treatment group were not inferior
compared with those in the rebamipide plus pantoprazole
treatment group. There are many reports about the effect of
rebamipide on the ulcer healing rate after ESD.3,9,11,12 Those
studies showed that PPI plus rebamipide is superior to PPI
monotherapy for healing artificial ulcers after ESD. However,
there are no reports about the effect of polaprezinc on the
artificial ulcer healing rate after ESD compared with rebami-
pide. Polaprezinc, which is a complex chelating agent consisting
of L-carnosine and zinc, is widely used as a mucoprotective
agent to treat gastric ulcers.13 The mechanisms of polaprezinc
are independent of prostaglandin, and polaprezinc has anti-
inflammatory and antioxidant effects.14,15 The zinc L-carnosine
ameliorates hydrochloric acid-induced mucosal injury by
inducing heat shock protein (HSP)-72 expression.16 The over-
expression of HSP72 protects various organs and cells including
gastric mucosal cells against stress conditions.17,18 One study
compared the effects of polaprezinc with those of rebamipide
on gastric mucosal protection.19 Polaprezinc showed gastric
mucosal protection similar to rebamipide by reducing the levels
of inflammatory cytokines and increasing the expression of
antioxidant enzymes, growth factors, and HSP. In addition,
polaprezinc is helpful for facilitating heal in various conditions,
such as radiation, chemotherapy injury, liver fibrosis, and
inflammatory bowel disease.20 Polaprezinc was used to heal
iatrogenic ulcers after ESD in only 1 study.8 The PPI plus
polaprezinc group showed significantly better ulcer healing and
more prevention of protrusion of the ulcer base, indicating that
this group had a higher quality of ulcer healing than the PPI
monotherapy group.
In this study, the PPI plus polaprezinc group showed
noninferiority in ulcer healing compared with the PPI plus
rebamipide group. In addition, the only predictor for a
higher than average ulcer healing rate was the short proce-
dure time. The long procedure time was an independent risk
factor for a low ulcer healing rate, and this result might be
associated with the use of more electrocautery during ESD.
Electrocautery has been known to result in proper muscle
damage.21 Therefore, electrocautery caused delayed ulcer
healing after ESD.22 In addition, the patients in the PPI plus
rebamipide group took 100mg rebamipide 3 times a day











Age (mean±SD) (y) 63.1± 8.8 63.1± 8.8 0.968
Sex 0.747
Male 78 (75.0) 82 (77.4)
Female 26 (25.0) 24 (22.6)
Histopathology 0.963
Adenoma 52 (50.0) 55 (51.9)
Carcinoma 48 (46.2) 47 (44.3)
Other 4 (3.8) 4 (3.8)
Location 0.252
Upper stomach 52 (50.0) 64 (60.4)
Middle stomach 39 (37.5) 34 (32.1)
Lower stomach 13 (12.5) 8 (7.5)
Gross tumor appearance 0.598
Elevated 66 (63.5) 65 (61.3)
Flat 17 (16.3) 14 (13.2)
Depressed 21 (20.2) 27 (25.5)
Longest diameter of the
tumor (mean±SD)
(mm)
13.8± 6.5 15.5± 7.1 0.076
Post-ESD ulcer size
(mean±SD) (mm2)
865.2± 477.1 888.2± 422.8 0.712
Specimen size after fixation
(mean±SD) (mm2)
876.2± 440.6 878.6± 430.2 0.968
En-bloc resection rate 102 (98.1) 105 (99.1) 0.620
Procedure time
(mean±SD) (min)
29.9± 29.7 26.5± 20.8 0.334
Smoker 27 (26.0) 25 (23.6) 0.750
Diabetes mellitus 9 (8.7) 17 (16.0) 0.142
Hypertension 41 (39.4) 47 (44.3) 0.487
Helicobacter pylori
infection
35 (33.7) 51 (48.1) 0.036
Body mass index
(mean±SD) (kg/m2)
24.6± 2.7 24.0± 2.9 0.153
ESD indicates endoscopic submucosal dissection.
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and the patients in the PPI plus polaprezinc group took
75 mg of polaprezinc twice a day. Therefore, one advantage
of polaprezinc compared with rebamipide is its twice a day
dosing. However, the cost of polaprezinc was 216 Korean
won (KRW) and rebamipide 99 KRW, respectively.
Therefore, the daily cost of polaprezinc was 432 KRW and
rebamipide 297 KRW. The cost of polaprezinc was higher
than that of rebamipide.
There is no fundamental guideline to determine the
appropriate PPI dose and treatment duration for iatrogenic
ulcer healing. Some studies reported variable treatment dura-
tion (1, 2, 4, and 8wk) and PPI dose (half or full dose) for ESD
ulcers.23–26 The predictors for delayed ulcer healing have been
known to be the tumor location, comorbidity, larger tumor
size, and electrocoagulation.22,27 In this study, the patients took
oral PPI plus rebamipide or polaprezinc for 4 weeks. The
average ulcer healing rate was 90.5%. This result was com-
parable with that of previous studies.9,19 However, the pro-
portion of patients with scarring stage was low (16/199, 8.0%).
Therefore, we could not evaluate the quality of ulcer healing
well. Shin et al9 reported that the scarring stage rate at 4 weeks
was 20.8% (53/255) after ESD in both the PPI and rebamipide
and PPI monotherapy groups. Furthermore, Nakamura et al12
showed that the scarring stage rate at 4 weeks was 14.4% (15/
104) after ESD in both the PPI and rebamipide and PPI
monotherapy groups. Although the scarring stage rate at 4
TABLE 2. Ulcer Healing Rates at 4 Weeks After ESD










Longest diameter of the ulcer (mm)
Initial 35.5± 9.4 36.0± 8.8 0.668 35.5± 9.6 35.7± 8.7 0.838
4 wk after ESD 11.8± 8.1 12.0± 8.2 0.917 12.0± 8.1 12.1± 8.3 0.892
Area of the ulcer (mm2)
Initial 865.2± 477.1 888.2± 422.8 0.712 866.0± 488.5 871.9± 415.7 0.926
4 wk after ESD 96.6± 155.4 93.4± 140.9 0.881 99.9± 159.4 97.2± 145.8 0.904
Healing rate at
4 wk (%)
90.3 91.4 0.523 89.9 91.1 0.531
Scar stages at 4 wk 10 (9.6) 11 (10.4) 0.953 7 (7.1) 9 (9.0) 0.846
ESD indicates endoscopic submucosal dissection; PPI, proton pump inhibitor.
TABLE 3. Predictors of Higher Ulcer Healing Rate at 4 Weeks After ESD in Univariate Analysis










Initial longest diameter of the ulcer (mm)
< 35 49 (91.4) 48 (92.6) 0.575 47 (91.1) 46 (92.4) 0.579
≥ 35 55 (88.2) 58 (90.0) 0.501 52 (87.7) 54 (89.5) 0.512
Initial area of the ulcer (mm3)
< 800 51 (90.2) 54 (92.4) 0.316 49 (90.0) 52 (92.2) 0.313
≥ 800 53 (89.2) 52 (89.9) 0.803 50 (88.7) 48 (89.3) 0.830
Procedure time (min)
< 21 46 (93.5) 57 (92.1) 0.540 43 (93.2) 54 (91.8) 0.566
≥ 21 58 (86.7) 49 (90.1) 0.196 56 (86.4) 46 (89.6) 0.239
Age (y)
< 64 47 (90.3) 56 (90.4) 0.962 46 (90.1) 53 (90.0) 0.948
≥ 64 57 (89.2) 50 (92.1) 0.286 53 (88.6) 47 (91.8) 0.257
Pathology
Adenoma 52 (91.0) 55 (92.1) 0.609 48 (90.4) 53 (91.9) 0.515
Carcinoma 48 (89.3) 47 (89.6) 0.900 47 (89.1) 43 (89.0) 0.955
Other 4 (78.3) 4 (96.9) 0.192 4 (78.3) 4 (96.9) 0.192
Location
Antrum 52 (89.5) 64 (92.3) 0.235 49 (89.0) 59 (91.8) 0.243
Other 52 (89.9) 42 (89.5) 0.880 50 (89.6) 41 (89.4) 0.939
Helicobacter pylori infection
No 69 (89.1) 55 (90.6) 0.546 64 (88.4) 52 (90.2) 0.490
Yes 35 (91.0) 51 (91.8) 0.720 35 (91.0) 48 (91.5) 0.840
Combined diseases
No 56 (88.2) 50 (90.6) 0.377 54 (87.8) 48 (90.3) 0.376
Yes 48 (91.5) 56 (91.7) 0.920 45 (91.1) 52 (91.3) 0.927
ESD indicates endoscopic submucosal dissection; PPI, proton pump inhibitor.
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weeks herein was lower than that in other studies, the incidence
of bleeding was low (1/210, 0.4%). This low bleeding rate might
be due to complete electrocoagulation of exposed vessels of the
iatrogenic ulcer.
In a previous study, polaprezinc showed better ulcer
healing and prevention of protrusion of the ulcer base after
ESD.8 In this study, we did not evaluate the effects of quality of
ulcer healing after ESD in the polaprezinc plus PPI group
because the proportion of patients with ulcer scarring stage was
low. Further studies will be needed to investigate the effects of
polaprezinc on the quality of ulcer healing.
In conclusion, polaprezinc plus PPI treatment showed
noninferiority to rebamipide plus PPI treatment in the
4-week ESD-induced ulcer healing rate.
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